Payment overview · 2025
General Payments
$724.28
43 reported records · 14 companies
Healthcare provider profile · identity verified
Pankaj Shukla, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BAKERSFIELD, CA · NPI 1114937190
Verified facts
What the public records show
CMS Open Payments records show Pankaj Shukla, MD received $724.28 in general payments during 2025 across 43 reported records.
Amgen Inc. accounted for 20.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 413 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 422 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 478 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $149.91 | 20.7% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $102.51 | 14.2% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $80.76 | 11.2% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $71.92 | 9.9% | 4 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $59.27 | 8.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.19 | 7.9% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $53.55 | 7.4% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.36 | 5.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.03 | 3.2% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $18.84 | 2.6% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $18.78 | 2.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.51 | 2.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $17.28 | 2.4% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $14.37 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $681.78 | 42 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $149.91 | 13 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $149.91 | 13 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $80.76 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $80.76 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $71.92 | 4 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $59.27 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $57.19 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $53.55 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $39.36 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $32.21 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.97 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.03 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| BARRIGEL Normalized: barrigel |
Device | Teleflex LLC | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $14.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 413 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 422 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 478 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 117 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
57 | 36 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
413 | 95 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
422 | 75 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
117 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
478 | 91 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1540 | 476 |
| Losartan Potassium | Losartan Potassium | 1158 | 344 |
| Levothyroxine Sodium | Levothyroxine Sodium | 917 | 259 |
| Metformin Hcl | Metformin Hcl | 792 | 251 |
| Amlodipine Besylate | Amlodipine Besylate | 779 | 248 |
| Gabapentin | Gabapentin | 760 | 278 |
| Pantoprazole Sodium | Pantoprazole Sodium | 646 | 255 |
| Januvia | Sitagliptin Phosphate | 618 | 115 |
| Ozempic | Semaglutide | 478 | 91 |
| Azithromycin | Azithromycin | 469 | 334 |
| Diclofenac Sodium | Diclofenac Sodium | 462 | 194 |
| Tamsulosin Hcl | Tamsulosin Hcl | 427 | 137 |
| Jardiance | Empagliflozin | 422 | 75 |
| Lisinopril | Lisinopril | 421 | 140 |
| Farxiga | Dapagliflozin Propanediol | 413 | 95 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 410 | 136 |
| Omeprazole | Omeprazole | 399 | 127 |
| Carvedilol | Carvedilol | 391 | 125 |
| Furosemide | Furosemide | 366 | 139 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 348 | 141 |
| Alprazolam | Alprazolam | 307 | 64 |
| Linzess | Linaclotide | 277 | 80 |
| Mounjaro | Tirzepatide | 270 | 56 |
| Tramadol Hcl | Tramadol Hcl | 268 | 98 |
| Hydralazine Hcl | Hydralazine Hcl | 255 | 87 |
| Metoprolol Tartrate | Metoprolol Tartrate | 254 | 82 |
| Potassium Chloride | Potassium Chloride | 251 | 90 |
| Naproxen | Naproxen | 249 | 135 |
| Clopidogrel | Clopidogrel Bisulfate | 239 | 80 |
| Baclofen | Baclofen | 235 | 107 |
| Famotidine | Famotidine | 231 | 94 |
| Prednisone | Prednisone | 202 | 132 |
| Atenolol | Atenolol | 196 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 196 | 110 |
| Montelukast Sodium | Montelukast Sodium | 189 | 69 |
| Glimepiride | Glimepiride | 179 | 54 |
| Ezetimibe | Ezetimibe | 177 | 53 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 173 | 36 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 169 | 100 |
| Escitalopram Oxalate | Escitalopram Oxalate | 169 | 52 |
| Alendronate Sodium | Alendronate Sodium | 163 | 52 |
| Eliquis | Apixaban | 162 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 158 | 53 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 156 | 123 |
| Doxazosin Mesylate | Doxazosin Mesylate | 147 | 50 |
| Levofloxacin | Levofloxacin | 143 | 119 |
| Duloxetine Hcl | Duloxetine Hcl | 141 | 49 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 141 | 60 |
| Pregabalin | Pregabalin | 141 | 38 |
| Ibuprofen | Ibuprofen | 140 | 81 |
| Nifedipine Er | Nifedipine | 140 | 46 |
| Trazodone Hcl | Trazodone Hcl | 139 | 44 |
| Trulicity | Dulaglutide | 139 | 22 |
| Finasteride | Finasteride | 138 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 138 | 41 |
| Entresto | Sacubitril/Valsartan | 136 | 25 |
| Meloxicam | Meloxicam | 134 | 55 |
| Glipizide | Glipizide | 127 | 42 |
| Donepezil Hcl | Donepezil Hcl | 125 | 39 |
| Sertraline Hcl | Sertraline Hcl | 124 | 46 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 117 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 116 | 72 |
| Simvastatin | Simvastatin | 116 | 35 |
| Nebivolol Hcl | Nebivolol Hcl | 113 | 35 |
| Amitriptyline Hcl | Amitriptyline Hcl | 111 | 42 |
| Nystatin | Nystatin | 108 | 65 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 108 | 63 |
| Myrbetriq | Mirabegron | 107 | 28 |
| Clonidine Hcl | Clonidine Hcl | 101 | 38 |
| Meclizine Hcl | Meclizine Hcl | 97 | 59 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 92 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 91 | 23 |
| Fluconazole | Fluconazole | 89 | 54 |
| Ropinirole Hcl | Ropinirole Hcl | 86 | 39 |
| Clonazepam | Clonazepam | 83 | 20 |
| Cephalexin | Cephalexin | 79 | 71 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 78 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 77 | 28 |
| Advocate Pen Needles | Pen Needle, Diabetic | 76 | 26 |
| Mirtazapine | Mirtazapine | 76 | 42 |
| Allopurinol | Allopurinol | 73 | 26 |
| Xarelto | Rivaroxaban | 73 | 13 |
| Labetalol Hcl | Labetalol Hcl | 72 | 18 |
| Spironolactone | Spironolactone | 71 | 28 |
| Tresiba Flextouch U-200 | Insulin Degludec | 70 | 14 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 70 | 24 |
| Paxlovid | Nirmatrelvir/Ritonavir | 69 | 67 |
| Pioglitazone Hcl | Pioglitazone Hcl | 69 | 20 |
| Topiramate | Topiramate | 69 | 25 |
| Tresiba Flextouch U-100 | Insulin Degludec | 68 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 67 | 61 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 65 | 17 |
| Warfarin Sodium | Warfarin Sodium | 64 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 18 |
| Novolog Flexpen | Insulin Aspart | 63 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 62 | 57 |
| Risperidone | Risperidone | 62 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 61 | 25 |
| Valsartan | Valsartan | 61 | 17 |
| Celecoxib | Celecoxib | 59 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 59 | 22 |
| Midodrine Hcl | Midodrine Hcl | 59 | 19 |
| Lorazepam | Lorazepam | 58 | 12 |
| Prolia | Denosumab | 57 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 56 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | 21 |
| Nitroglycerin | Nitroglycerin | 55 | 41 |
| Veo Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 55 | 19 |
| Zenpep | Lipase/Protease/Amylase | 54 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 52 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 27 |
| Tradjenta | Linagliptin | 51 | 12 |
| Telmisartan | Telmisartan | 50 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 49 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 24 |
| Hydrocortisone | Hydrocortisone | 49 | 26 |
| Mupirocin | Mupirocin | 49 | 31 |
| Lovastatin | Lovastatin | 48 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 13 |
| Repatha Sureclick | Evolocumab | 46 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 36 |
| Synthroid | Levothyroxine Sodium | 46 | 15 |
| Amoxicillin | Amoxicillin | 44 | 37 |
| Benazepril Hcl | Benazepril Hcl | 44 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 15 |
| Moxifloxacin | Moxifloxacin Hcl | 42 | 35 |
| Amiodarone Hcl | Amiodarone Hcl | 37 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | suppressed |
| Lactulose | Lactulose | 36 | 25 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 36 | 33 |
| Ssd | Silver Sulfadiazine | 36 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 11 |
| Procto-Med Hc | Hydrocortisone | 34 | 16 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 33 | 33 |
| Ketoconazole | Ketoconazole | 32 | 20 |
| Terazosin Hcl | Terazosin Hcl | 32 | 11 |
| Gemfibrozil | Gemfibrozil | 31 | 14 |
| Levetiracetam | Levetiracetam | 31 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 28 | 27 |
| Fluocinonide | Fluocinonide | 28 | 15 |
| Loperamide | Loperamide Hcl | 28 | 20 |
| Rybelsus | Semaglutide | 28 | suppressed |
| Mupirocin | Mupirocin Calcium | 27 | 18 |
| Irbesartan | Irbesartan | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | 11 |
| Droplet Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Metronidazole | Metronidazole | 25 | 13 |
| Valacyclovir | Valacyclovir Hcl | 25 | 17 |
| Metolazone | Metolazone | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Calcitriol | Calcitriol | 23 | suppressed |
| Gemtesa | Vibegron | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Praluent Pen | Alirocumab | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 21 | 18 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | 17 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Enulose | Lactulose | 16 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Klor-Con 10 | Potassium Chloride | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | 11 |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Ciclopirox | Ciclopirox | 14 | 11 |
| Insulin Aspart Prot Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Ofloxacin | Ofloxacin | 14 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Hailey 24 Fe | Norethindrone-E.Estradiol-Iron | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 11 | 11 |
| Epinephrine | Epinephrine | 11 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $724.28 · 43 records | Amgen Inc. | ACCRUFER, AFREZZA, AIRSUPRA, BARRIGEL, BREZTRI, FARXIGA, FREESTYLE LIBRE 3, Fluad, Flucelvax, GEMTESA, IBSRELA, JARDIANCE, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error